NI201300007A - A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL. - Google Patents

A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL.

Info

Publication number
NI201300007A
NI201300007A NI201300007A NI201300007A NI201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A
Authority
NI
Nicaragua
Prior art keywords
csf
stimulating factor
conjugate
granulocite
cologne
Prior art date
Application number
NI201300007A
Other languages
Spanish (es)
Inventor
Veniaminovna Chernovskaya Tatyana
Alexandrovich Denisov Lev
Valentinovich Morozov Dmitriy
Georgievna Rudenko Elena
Leonidovna Morozova Elena
Original Assignee
Closed Join Stock Company Biocad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Closed Join Stock Company Biocad filed Critical Closed Join Stock Company Biocad
Publication of NI201300007A publication Critical patent/NI201300007A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a farmacéuticos y medicinas, específicamente, a un nuevo conjugado fisiológicamente de granulocita colonia estimulante factor (G -CSF) con la fórmula general: (I) Donde: n - intergers de 681 a 1,000; m - interger 4; NªH - G - CSF - Natural o recombinante polipéptido, teniendo actividad de G - CSF. La invención También está relacionada a medicinas conteniendo el conjugado reclamado de fórmula (1), composiciones farmacéuticas, el uso de conjugado de fórmula (1) para drogas y medicinas con granulocita colonia estimulante factor como un ingrediente activo, se aproxima a prevenir y/o tratar la neutropenia, el contenedor que contiene la composición farmacéutica.The present invention relates to pharmaceuticals and medicines, specifically, to a new physiologically conjugate of granulocyte colony stimulating factor (G -CSF) with the general formula: (I) Where: n - intergers from 681 to 1,000; m - interger 4; NªH-G-CSF-Natural or recombinant polypeptide, having G-CSF activity. The invention is also related to medicines containing the claimed conjugate of formula (1), pharmaceutical compositions, the use of conjugate of formula (1) for drugs and medicines with granulocyte colony stimulating factor as an active ingredient, approaches to prevent and / or treat neutropenia, the container containing the pharmaceutical composition.

NI201300007A 2010-08-13 2013-01-18 A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL. NI201300007A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent

Publications (1)

Publication Number Publication Date
NI201300007A true NI201300007A (en) 2014-05-26

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300007A NI201300007A (en) 2010-08-13 2013-01-18 A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL.

Country Status (18)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
PH (1) PH12012502426A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
KR102083046B1 (en) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 Methods for treating neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
MX2016010699A (en) 2014-02-18 2017-10-11 Children's Hospital Los Angeles COMPOSITIONS AND METHODS TO TREAT NEUTROPENIA.
PE20170769A1 (en) * 2014-07-14 2017-07-04 Gennova Biopharmaceuticals Ltd NOVEL PROCEDURE FOR PURIFICATION OF RHU-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
KR102874958B1 (en) * 2020-03-17 2025-10-21 드럭리큐어 에이피에스 Liquid formulation of GM-CSF for inhalation
WO2021188869A2 (en) * 2020-03-20 2021-09-23 Amgen Inc. Determination of free n-terminus of pegfilgrastim using an acid protease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006952A1 (en) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases

Also Published As

Publication number Publication date
EA201101035A1 (en) 2012-02-28
CO6670557A2 (en) 2013-05-15
CR20130020A (en) 2013-02-20
CU20130012A7 (en) 2013-04-19
CN103140499B (en) 2014-12-17
CU24139B1 (en) 2015-12-23
MA34525B1 (en) 2013-09-02
KR101549457B1 (en) 2015-09-02
MY160732A (en) 2017-03-15
CN103140499A (en) 2013-06-05
RU2446173C1 (en) 2012-03-27
PH12012502426A1 (en) 2021-06-02
ECSP13012399A (en) 2013-05-31
RS20130094A1 (en) 2013-08-30
CL2013000400A1 (en) 2013-07-26
EA019043B1 (en) 2013-12-30
WO2012021088A1 (en) 2012-02-16
PE20131085A1 (en) 2013-10-10
KR20130043167A (en) 2013-04-29
SG187572A1 (en) 2013-03-28
DOP2013000003A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
NI201300007A (en) A NEW CONJUGATE OF COLOGNE GRANULOCITE - STIMULATING FACTOR (G -CSF) WITH POLYETHYLENE GLYCOL.
BR112013003045A2 (en) compound and pharmaceutical composition and uses thereof, sterile container and method for preparing pharmaceutical composition for administration
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
BR112013031268A8 (en) polypeptides
PH12014500249A1 (en) New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments
PH12013500152A1 (en) New aminopyrazoloquinazolines
EA201201050A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
ECSP13013024A (en) 1,3-OXAZINES AS INHIBITORS OF BACE1 AND / OR BACE2
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
EA201600366A1 (en) DERIVATIVES OF BENZIMIDAZOL-PROLINE
CR20130588A (en) HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE 2
BR112015000578A2 (en) complement pathway modulators and their uses
MX2013011086A (en) (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases.
EA201590805A1 (en) COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY
BR112012024712A2 (en) trpv1 vanilloid receptor antagonists with a bicyclic moiety
MX2015013480A (en) Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells.
BR112014015630A8 (en) fluoromethyl-5,6-dihydro-4h- [1,3] oxazins, their uses, and pharmaceutical composition
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
PH12014502619A1 (en) Novel dosage and formulation
CY1115600T1 (en) Piperazines as Anthelmintic Agents
TR201007250A2 (en) Formulation containing cellobiose.
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
UA60688U (en) pharmaceutical composition for the treatment of respiratory diseases and allergic diseases
TH134004A (en) New type of conjugate of granulosite Colony-Stimulating Factor (G-CSF) with Polyethylene Glycol